SkyePharma, Blue Acquisition, Paul Capital Partners deal

SKP completed the previously announced sale of its injectable business, including DepoDur morphine to treat post-surgical pain, to Blue Acquisition for $20 million in cash and up to $62 million in milestones, plus royalties (see BioCentury, Jan. 15). Blue Acquisition is an acquisition vehicle controlled and funded by investors including MPM Capital; OrbiMed; and Sanderling Ventures. ...